^
    8ms
    KEYNOTE-914: BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab (clinicaltrials.gov)
    P1, N=87, Completed, Eikon Therapeutics | Active, not recruiting --> Completed | N=50 --> 87 | Trial completion date: Aug 2024 --> Apr 2024 | Trial primary completion date: Aug 2024 --> Mar 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • resiquimod sulfate (EIK1001)
    8ms
    BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
    P1, N=40, Completed, Eikon Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Tecentriq (atezolizumab) • resiquimod sulfate (EIK1001)
    9ms
    KEYNOTE-G04: Safety and Efficacy of EIK1001-006 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. (clinicaltrials.gov)
    P2/3, N=740, Recruiting, Eikon Therapeutics | Initiation date: Nov 2024 --> Apr 2025 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    Keytruda (pembrolizumab) • resiquimod sulfate (EIK1001)
    11ms
    Examination of the potential clinical application of 5DEX-0509R, the tumor macrophage-targeting nanomedicine. (PubMed, Cytokine)
    To solve this, we have developed dextran-based TAM targeting activator conjugate (D-TAC) technology which successfully uses tumor-associated macrophages (TAMs) to deliver the TLR7 agonist DSP-0509...In this study, we compared the anti-tumor effects of EIK1001 and 5DEX-0509R, and analyzed its unique immune reaction against tumors to evaluate whether 5DEX-0509R is suitable for further clinical study...We also found that 5DEX-0509R synergistically suppresses tumors with oxaliplatin by changing M2 macrophages that cause oxaliplatin to become resistant to antitumor M1 macrophages. In addition, 5DEX-0509R caused a rapid but not sustained cytokine elevation in both rats and dogs. We believe 5DEX-0509R is worth pursuing for clinical trials.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    oxaliplatin • guretolimod (DSP-0509) • resiquimod sulfate (EIK1001)
    1year
    KEYNOTE-G04: Safety and Efficacy of EIK1001-006 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. (clinicaltrials.gov)
    P2/3, N=740, Not yet recruiting, Eikon Therapeutics
    New P2/3 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • resiquimod sulfate (EIK1001)
    over1year
    BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Eikon Therapeutics | Trial primary completion date: Mar 2024 --> Aug 2024 | Trial completion date: Mar 2024 --> Aug 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • resiquimod sulfate (EIK1001)
    over1year
    BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Eikon Therapeutics | Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Mar 2024 --> Jul 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Tecentriq (atezolizumab) • resiquimod sulfate (EIK1001)
    almost2years
    A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Eikon Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • resiquimod sulfate (EIK1001)
    almost2years
    BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Eikon Therapeutics | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Tecentriq (atezolizumab) • resiquimod sulfate (EIK1001)
    almost2years
    BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Eikon Therapeutics | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • resiquimod sulfate (EIK1001)
    almost2years
    A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, Eikon Therapeutics
    New P2 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • resiquimod sulfate (EIK1001)
    over2years
    BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Eikon Therapeutics | Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Tecentriq (atezolizumab) • resiquimod sulfate (EIK1001)